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Abstract. Stem cells are a powerful resource for cell-
based transplantation therapies in osteodegenerative
disorders, but before some kinds of stem cells can be
applied clinically, several aspects of their expansion
and differentiation need to be better controlled. Wnt
molecules and members of the Wnt signaling cascade
have been ascribed a role in both these processes in
vitro as well as normal development in vivo. However
some results are controversial. In this review we will
present the hypothesis that both canonical and non-
canonical signaling are involved in mesenchymal cell
fate regulation, such as adipogenesis, chondrogenesis
and osteogenesis, and that in vitro it is a timely switch
between the two that specifies the identity of the
differentiating cell. We will specifically focus on the in
vitro differentiation of adipocytes, chondrocytes and
osteoblasts contrasting embryonic and mesenchymal
stem cells as well as the role of Wnts in mesenchymal
fate specification during embryogenesis.
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Introduction
Mature chondrocytes, osteoblasts and adipocytes are
believed to arise from a common precursor cell, a stem
cell. Stem cells have gained significant attention of
late, since they hold great promise as a source for cell
therapy in general, and specifically for therapies
requiring adipocytes, chondrocytes and osteoblasts.
For example, chondrocytes do not normally regener-
ate themselves after injury and medicinal treatment
can only ameliorate joint disorders such as arthritis or
joint injuries. Here, transplantation of cells that are
able to reconstitute the tissue is often the only
measure to cure a disease state. Moreover, cellular
therapies with allogeneic stem cell-derived osteo-
blasts could become a treatment option for osteopo-
rosis and osteogenesis imperfecta, where the endog-
enous cells could theoretically regenerate, but would
carry a genetic defect. Stem cell-derived adipocytes
are also becoming increasingly attractive to the
cosmetic industry. Thus, stem cells can find application
in regenerative medicine and/or reconstructive sur-
gery.
To date, therapeutic applications of mesenchymal
stem cell culture methods as a source for these three
cell types have already been devised that withstand
clinical quality controls. However, we are just begin-
ning to understand the differentiation potential of
other types of stem cells, such as embryonic stem cells.
No matter what the final stem cell of choice for a
certain therapeutic approachwill be, it is imperative to
comprehend how stem cells switch from proliferation
to differentiation, a step that is critical for the normal* Corresponding author.
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development of every tissue, and how they switch
between alternating differentiation paths. However,
how the cell exits the cell cycle and decides between
alternate differentiation pathways is not completely
understood.
This review collates and examines recent insights into
regulatory decisions of stem cells with regard to the
adipogenic, osteogenic and chondrogenic program.
First, it descriptively compares embryonic and mes-
enchymal stem cells and illustrates their advantages
and caveats with respect to cell therapies and tissue
engineering. In addition, it will introduce known
transcription factors and other molecules thought to
be involved in the development of these above
mentioned cell types through an either direct or
indirect interactionwith theWnt pathway,which plays
an important role in embryo development in vivo and
has been implicated into regulation of self-renewal
and lineage diversification of stem cells in vitro.
Sources of stem cells with mesenchymal lineage
potential
Stem cells can be derived from various sources and
tissues. They can be sub-divided into two major
groups: embryonic and adult stem cells. Both exhibit
advantageous and disadvantageous characteristics for
their use in tissue engineering and differ in origin,
potency and therapeutic potential. Embryonic stem
cells (ESCs) represent a population of cells that, once
isolated, can be maintained in permanent culture for
over fourteen months [1] and have thus been descri-
bed as having an unlimited self-renewing capacity.
However, discussions and controversies governing
ethical issues surround their use in clinical applica-
tions. While the ethically uncontroversial adult stem
cells can be harvested from most adult tissues, one of
the limitations of these cells for their use in the clinic is
their compromised proliferative potential. Adult stem
cells, when isolated from younger donors, can only
proliferate 24–40 population doublings in vitro before
undergoing growth arrest. Those taken from older
donors exhibit even earlier replicative senescence due
to the absence of telomerase activity [2, 3] and
therefore the amount of stem cells that can be cultured
sometimes simply limits their clinical usage especially
for the repair of larger defects.
Embryonic stem cells
ESCs are derived from the inner cell mass of an
embryo at the blastocyst stage of development. These
cells are pluripotent and exhibit an extensive multi-
plication potential. Murine ESCs were first isolated
over twenty-five years ago [4, 5]. Asmany of the genes
are similar between murine and human ESCs [6], the
mouse model has become an important model system
for studying cell replacement therapy [reviewed in 7]
as well as the mechanisms for maintaining stem cell
renewal, early commitment and epigenetic phenom-
ena [8]. One of the first requirements to understand-
ing the mechanism of differentiation is to understand
how the cell maintains pluripotency. Once pluripo-
tency can be maintained in culture, we can start
researching the changes the cell must go through in
order to become another more specified cell type.
A mouse ESC is maintained in its pluripotent state
with the addition of Leukemia Inhibitory Factor (LIF)
[9] or when cultured on feeder layers [8]. LIF is a
member of the interleukin (IL)-6 cytokine family and
binds to the low affinity LIF receptor (LIFR), which is
expressed in the inner cell mass of mouse embryos
[10]. This binding activates a downstream cascade by
which transcription of pluripotency genes in the
nucleus is ultimately activated [reviewed in 11].
Whereas the common believe is that pluripotency is
actively switched on through addition of LIF, novel
insights are currently shifting this paradigm. In fact,
spontaneous differentiation of ESCs, in which path-
ways such as ERK1/2 are instrumental, must be
indirectly blocked to maintain pluripotency [12].
Therefore the correct terminology for factors such as
LIF should be differentiation inhibitor rather than
pluripotency factor.
The first human ESCs were derived just before the
turn of the century [13] opening up alternative
possibilities for stem cell therapy. However, the use
of ESCs as a tool in therapy for disease requires an
understanding of the differences between mouse and
human ESCs. There are some significant differences
between mouse and human ESCs with regard to
expression of markers and responsiveness to intrinsic
signals, such as LIF. LIF is not sufficient to maintain
pluripotency in human ESCs. Thus a variety of other
signaling molecules have been implicated in self-
renewal. Basic Fibroblast Growth Factor (bFGF) in
combination with noggin, bone morphogenic protein
(BMP) 4, activin A and Wnt3a [14–17] have been
described as supporting the ex vivo expansion of
undifferentiated human ESCs. More differences be-
tween the species lie particularly in morphology,
immunophenotype, and growth properties. For exam-
ple, mouse ESCs grow in three-dimensional attached
clusters, and have the appearance of a fried egg,
whereas human ESCs grow in flat colonies that have
distinct edges [reviewed in 18]. A set of alleged
“stemness” genes, such as Oct-4, nanog and Sox-2,
together with alkaline phosphatase and rex-1, serve as
markers for pluripotency [19–22]. The Oct-4/Sox-2/
nanog triad in particular, share a substantial number
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of target genes [23, 24]. On a more global level,
pluripotency seems to be controlled by polycomb
complexes that repress transcription of particular
chromosomal regions through epigenetic modifica-
tion of the chromatin structure [25]. More recently, a
special type of cell with pluripotent characteristics has
been described, which had been artificially obtained
by in vitro reprogramming of fibroblasts ectopically
expressing a set of the four transcription factorsOct-4,
Sox-2, c-myc and KLF4. In these so-called induced
pluripotent (iPS) cells the DNA methylation status
and chromatin state are similar to those of ESCs and
these cells can contribute to the germ-line upon
blastocyst injection [26, 27]. Although not ethically
controversial, unlike the true ESC, iPS cells share
some of the same concerns. As such, further research
is due to find out how teratoma formation upon
transplantation of non-fully differentiated cells can be
prevented.
Adult stem cells
In contrast to ESCs, adult stem cells are set aside
during embryonic development. In the adult body,
they reside in almost every tissue and are thus also
termed somatic stem cells. Capable ofmulti-lineage or
uni-lineage differentiation only, they resemble a stem
cell with amore restricted potential. Hence, compared
to ESCs, somatic stem cells are one or multiple steps
ahead in the differentiation process. A bone marrow
derived but non-hematopoetic stem cell population
commonly known as the mesenchymal stem cell
(MSC) comprises a population of multipotential
progenitors, which can give rise to multiple cell
lineages including osteoblasts, adipocytes, chondro-
cytes and myoblasts [28–30]. Most MSCs differen-
tiate relatively spontaneously into these lineages with
minimal growth factor supplementation of the culture
medium. Neuronal differentiation can also be ach-
ieved, but only with the addition of a complex cocktail
of specialized growth factors [31, 32]. In contrast,
MSCs can spontaneously express neural markers in
vitro as can the pluripotent stem cell markers Oct-4
and rex-1 [33]. Due to these controversial data it
therefore remains unclear whether neural differentia-
tion of MSCs occurs via a process called transdiffer-
entiation.
Although the most common source for MSCs is bone
marrow, cells with similar characteristics have also
been isolated from umbilical cord blood, fat aspirants,
connective tissue, skin and placenta [32, 34–38].
MSCs can be distinguished by their fibroblast-like
morphology and their characteristic of adhering to
plastic surfaces [39], but molecular or cell surface
markers are poorly defined. Therefore, the molecular
identification ofMSCs remains difficult. Some surface
markers have been associatedwithMSCs recently, but
have not been agreed on. The most widely used MSC
markers are CD90, CD73 and CD105 [40]. Stro1,
glycophorin A, D7-fib and low-affinity nerve growth
factor receptor p75, also denoted CD271, and con-
troversially CD45 have also shown some success in the
immuno-characterization of these cells [41–46]. Sur-
face markers for ESCs on the other hand are well
established, with SSEA-1 and alkaline phosphatase
specific for mouse ESCs [47] and TRA-181, TRA-160
and SSEA3/4 for human ESCs [48], with novel
molecular markers being added to the stemness
palette with increasing frequency.
Control of initial differentiation events through Wnts
As discussed above there are a number of molecules
that regulate the differentiation of adipocytes, osteo-
blasts and chondrocytes from stem or progenitor cells
in vivo and in vitro. The Wnt signaling pathway is one
of the pathways known to play a vital role in this
process. The Wnt family of ligands consists of a
number of highly evolutionarily-conserved secreted
glycoproteins involved in many developmental proc-
esses such as cell differentiation, polarity, cell migra-
tion, cell proliferation and regeneration [49–51].
Wnts are thus essential for normal embryogenesis,
but also actively participate in the regeneration of
adult tissues, such as colon, skin, hair follicles and
bone by controlling tissue specific adult stem cell
function [52, 53]. Hence, it is not surprising that genes
encoding Wnt pathway components are genetically
and epigenetically altered in human cancer and
disease [54].
The details of the Wnt signaling cascade have been
extensively covered elsewhere [55] and shall only
briefly be summarized here. The vertebrateWnts have
been historically divided into two functional groups;
those that induce secondary axis formation in Xen-
opus embryos and those that do not induce an axis.
The axis-inducing Wnts attach to the membrane
bound receptor Frizzled (Fzd) initiating a directed
signaling cascade that leads to the accumulation of b-
catenin (CatnB) [56] and was later named the canon-
ical pathway (Fig. 1). In addition to the Fzd receptor,
classical canonical Wnt molecules bind to a co-
receptor called low-density lipoprotein related pro-
tein 5/6 (LRP5/6) [57, 58].
In the absence of Wnt signal, a multiprotein complex
involving axin, casein kinase 1, glycogen synthase
kinase 3 beta (GSK-3b), adenomatous polyposis coli
(APC) and Dishevelled (Dsh) mediate CatnB degra-
dation (Fig. 2). APC and axin are two scaffold proteins
which enable GSK-3b to bind and phosphorylate
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CatnB. This phosphorylation creates binding sites for
b-TrCP, an F-box protein in the E3 ubiquitin ligase
complex, to attach and tag CatnB for proteasome-
mediated degradation [59, 60].
The intracellular tail of Fzds contains the motif
KTxxxW which will recruit phosphorylated Dsh to
the membrane when a Wnt ligand binds [61]. Dsh is a
modular cytoplasmic protein that, once activated,
suppresses the phosphorylation activity of GSK3b by
interacting with proteins of the degradation complex
[62, 63].
CatnB can also be regulated in a non-GSK3bmanner
by recruitment of axin to the membrane by LRP5/6,
which causes axin degradation. As a consequence,
CatnB is no longer bound to the APC-axin-GSK3b
complex.
In both cases, degradation of CatnB is prevented and
accumulates in the nucleus, where it binds to the
transcription factors lymphoid enhancer factor (LEF)
and/or T-cell factor (TCF) triggering downstream
gene transcription (including that of c-myc and Cyclin
D1) by converting LEF/TCF from transcriptional
repressor to activator [reviewed in 64; 65–67]. LEF-
1/TCF proteins bind to the CatnB central armadillo
repeats in a region that largely overlaps with the
binding sites forAPC [68]. Because of the competition
between APC and LEF for overlapping regions of the
CatnB molecule, CatnB cannot interact with APC
when bound to LEF and vice versa, a mechanism
whereby transcriptional activation of its targets can be
controlled.
The non-axis producing, non-canonical Wnts, in turn,
do not signal through CatnB and in some cases inhibit
nuclear CatnB activity [69]. Similar to the canonical
pathway, the non-canonical pathways also require Fzd
as the receptor.However, they do not require LRP5/6,
which typically acts as a co-receptor in canonical
signaling, but instead a proteoglycan protein called
Knypek [70]. Downstream, Dsh is also involved in
further transducing the non-canonical signal. How-
ever, it appears that different Dsh domains are
required in the canonical versus the non-canonical
pathway [71, 72]. For instance, recruitment of Dsh to
the cell membrane occurs through its DEP domain
only in the non-canonical pathway [71, 73].
This non-canonical pathway is less characterized and
the proteins involved, as well as their interactions in
the cascade, are controversial. To date, the non-
canonical pathway has been split into 3 sub-pathways,
2 of which release calcium ions into the cytoplasm.
These 2 pathways are involved in cell adhesion and
cell shape. The third pathway is involved in cell
polarity (Fig. 1).
To complicate things, the canonical and non-canonical
pathways are not distinct as some Wnts can signal
through both pathways [74] and some downstream
Figure 1. Canonical and non-
canonical Wnt signaling path-
ways. There are at least three
different intracellular Wnt sig-
naling transduction pathways.
These pathways are the Wnt/
CatnB pathway (canonical path-
way), the Wnt/Ca2+ pathway and
theWnt/planar cell polarity path-
way. Both theWnt/Ca2+ pathway
and the Wnt/planar cell polarity
pathway are combined as the
non-canonical pathway, which
involve the downstream mem-
bers calmodulin kinase II (Cam-
KII), protein kinaseC (PKC) and
c-jun kinase (JNK). See text for
more details.
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targets are involved in both, such asDishevelled (Dsh)
(Fig. 1) [reviewed in 75]. The combination of pathway
members seems to depend on the cellular context.
In stem cells, Wnt/CatnB signaling regulates cellular
function at the level of maintaining stemness. How-
ever, both the canonical (nuclear CatnB activity) as
well as the non-canonical cascade (blockage of
nuclear CatnB activity) also control differentiation
(Fig. 2).
Here, the activity level of CatnB in the nucleus seems
to play an important role. In ESCs, overexpression of
the canonical Wnt1 or stabilized CatnB results in the
inhibition of neural differentiation and in the activa-
tion of cell cycle genes such as c-myc and cyclins
supporting self-renewal [76, 77]. Additionally, GSK-
3b can phosphorylate p53, which in turn suppresses
nanog expression thus supporting differentiation [78].
Blockage of GSK-3b would therefore assist in main-
tenance of pluripotency, possibly through regulation
of p53 and nanog. These data have been verified by
Sato et al. [79], who artificially inhibited GSK-3bwith
BIO perpetuating Oct-4 expression. Addition of
Wnt3a supported pluripotency in human and mouse
ESCs even without a feeder layer or LIF, respectively,
and sustained the characteristic phenotype of the
respective cultures. Independent from Wnt ligand
binding, the natural upstream negative regulator of
GSK-3b in ESCs was recently identified to be PI3K
and Akt [80]. Finally, mutations in APC that are
associated with increased intracellular doses of CatnB
interfere with ESC differentiation into the three germ
layers [81].
The first switch in Wnt signaling occurs when the
ESC decides to differentiate. Whereas CatnB uses
the cofactor CREB-binding protein (CBP) to regu-
late the expression of pluripotency and cell cycle
associated genes to maintain stemness, upon differ-
entiation CatnB/p300 is activating a different set of
target genes, thereby initiating differentiation [82].
Here, c-myc is one of these downstream genes and
since it is targeting cell cycle regulators it is respon-
sible for continuous proliferation of the differentiat-
ing cells. In addition, the expression of the non-
canonical Wnt5a is abruptly increased upon differ-
entiation (Fig. 3).
Aside from controlling self-renewal and early differ-
entiation, the Wnt signaling pathway thereafter spe-
cifically regulates the lineage-specification of mesen-
chymal precursor cells into adipocytes, osteoblasts
and chondrocytes [83–85]. However, not only chem-
ical cues, but also physical activation such as cell
density and cell shape appear to play a role in lineage
commitment. Mesenchymal condensations are char-
acterized by increased cell density and cell-cell
adhesion. Lower cell densities seem to support
osteoblast differentiation of MSCs whereas higher
cell densities cause the cells to condense, forcing cells
to become adipocytes [86]. In this context, cell shape
seems to be regulated by RhoA, a downstream target
of the non-canonical Wnt pathway. Moreover, N-
cadherin, a calcium dependent protein involved in
cell-cell adhesion, directly interacts with CatnB at the
plasma membrane [reviewed in 87]. This interaction
occurs specifically at the time of mesenchymal con-
Figure 2. Regulation of ESC differentiation through CatnB. Activation or blockage of nuclear CatnB activity controls lineage decisions.
The duration of the specific signal plays a role in the transcriptional activation of lineage-specific transcription factors. See text for details.
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densations before differentiation begins [87]. During
cellular differentiation into chondrocytes, N-cadherin
expression decreases along with CatnB expression
and with increased Collagen type IIa expression.
Therefore, the regulation of CatnB and N-cadherin in
cell-cell adhesion is necessary for mesenchymal con-
densations but not the subsequent differentiation of
chondrocytes.
Due to their pluripotent differentiation ability, ESCs
are ultimately capable of differentiating into meso-
dermal lineages (Fig. 4) – such as adipocytes, osteo-
blasts and chondrocytes [88–93].
Differentiation is commonly induced bywithdrawal of
differentiation inhibitors and physical aggregation of
the cells into embryoid bodies. Mesodermal and
endodermal cells appear with continued differentia-
tion [reviewed in 94], but the progression of differ-
entiation varies with the type of aggregation system
utilized. Brachyury (T-Bra), a transcription factor
expressed in the primitive streak in vivo, is detectable
on day three of differentiation. Whereas a prolonged
T-Bra expression until day seven has been described
elsewhere [94], we and others rather find two ex-
pression waves [95]. Studies from the Keller labora-
tory suggest that the first wave of T-Bra expression
marks a hemangioblast population and that sorted T-
Bra+ cells from the second wave give rise to cardio-
myocytes and represent a mesodermal population
[summarized in 96]. As adipocytes, osteoblasts and
chondrocytes form out of the mesoderm these events
might as well mark the first days of adipo-, osteo- and
chondrogenesis in vitro.
Molecules that characterize adipogenesis,
chondrogenesis and osteogenesis
Lineage relationships and transcription factors.After
the cell has started the differentiation program and
has been pushed toward the adipo-, chondro- or
osteogenic cell fate there are a number of genes that
are up-regulated at a specific time during differentia-
tion. These geneswill define the cell as a particular cell
type when observed through gene expression studies.
This section will introduce the molecules that charac-
terize the cell and are used effectively as signposts to
aid the researcher in distinguishing what stage a cell is
at during differentiation. The stages of differentiation
thesemolecules are expressed at provide a framework
for researchers to study the Wnt pathway and its
regulation of these differentiation programs, which is
outlined later in this review.
The relationship between each of these three cell
types can be outlined in a summary of the major
transcription factors that may be necessary for their
specification to their respective lineages. These tran-
scription factors include CCAAT/Enhancer binding
protein (C/EBP) alpha and peroxisome proliferator-
activated receptor (PPAR) gamma for adipocytes [97,
Figure 3. Exogenous factors control ESC fate. Whereas LIF, Wnt
signaling, BMP-4 and noggin contribute to the undifferentiated
phenotype and self-renewal of ESCs, withdrawal of LIF induces
embryoid body (EB) formation and differentiation. Within two to
threedays, a single cell layer of endodermal origin forms as an outer
sheet of the EB. Afterwards, various factors induce lineage
specification through up-regulating lineage-specific transcription
patterns thus pushing the cells to amature fate. Ins= Insulin,AA=
ascorbic acid, Dex = dexamethasone, RA = retinoic acid, VD3 =
vitamin D3.
Figure 4. Mesodermal specification in ESCs. During differentia-
tion of murine ESCs, the mesodermal marker T-Brachyury is
expressed in two waves from d3–5 and again from d7–9. In
contrast, the non-canonical Wnt5a is expressed with beginning
differentiation and its expression level decreases before the onset
of the first Brachyury wave. Later, Wnt5a expression is increased
around differentiation day 6–9 induced by vitamin D3.
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98], core binding factor alpha 1 (Cbfa1/Runx2) and
osterix for osteoblasts [99, 100] and Sox9 for chon-
drocytes [101]. These lineage-specific transcription
factors, although mostly regulating their own tran-
scription through a positive feedback mechanism (i.e.
Runx2 and C/EBPa), can also inhibit differentiation
of other lineages by suppressing gene expression. As
such, Runx2 null chondrocytes revert into adipocytes
in vitro [102]. PPARg on the other hand inhibits
Runx2 expression and thus terminal osteoblast differ-
entiation [103].
Once differentiation has been initiated, further
lineage decisions seem to be largely regulated by
members of the nuclear hormone receptor family
including PPAR, retinoic acid and retinoid X recep-
tors (RAR/RXR) and vitamin D3 receptors (VDR),
which are indeed commonly used to trigger differ-
entiation in vitro [92, 93, 104]. All three receptors are
activated by ligands and translocated to the nucleus.
Through the binding to hormone response elements
within the promoter of target genes, these receptors
will then control gene expression [reviewed in 105].
During differentiation of ESCs towards adipocytes
PPARg is activated [104], supplementation with
retinoic acid (RA) leads to enhanced chondrogenesis
[93] and vitamin D3 (VD3) activates the osteogenic
program [92, 104]. Interestingly, both PPAR and
VDR heterodimerize with the RXR receptor [105,
106] and transcriptional activation by both are
controlled through interactions with co-activators
and co-repressors [107]. Signaling pathways known
to be involved in the nuclear receptor family and
consequent interactions are the mitogen-activated
protein kinase (MAPK), phosphinositide 3 kinase
(PI3K)/Akt and Wnt pathways [reviewed in 105].
Thus, all three nuclear receptorsmediate their effects
through ligand binding, gene activation and post
translational events.
Adipogenesis. Adipogenesis, like the development of
other lineages, is a tightly controlled, well-orchestrat-
ed sequence of events regulated by positive and
negative stimuli [108]. Differentiation of the multi-
potent stem cell line C3H10T1/2 and preadipocyte cell
lines, such as 3T3-L1 and 3T3-F442A cells into
adipocytes can be divided into four phases: I) Pre-
confluent proliferation II) confluence/growth arrest
III) hormonal induction/ clonal expansion IV) per-
manent growth arrest/ terminal differentiation. The
later part is controlled by specific transcription factors
involving C/EBP proteins and PPARg, which act in a
time-regulated fashion.
Specifically, adipogenesis is controlled by the C/EBP
family members C/EBPa, b, d and CHOP-10 [re-
viewed in 109]. Although C/EBPb is expressed
immediately after induction of differentiation, only
when the cells enter the mitotic clonal expansion
phase (phase III) the DNA binding capacity of C/
EBPb is activated [110, 111]. As a regulator of
terminal adipogenesis entering phase IV, C/EBPb
subsequently activates transcription of C/EBPa
through binding to a C/EBP regulatory element in
the C/EBPa promoter [112].
The second adipocyte-specific transcription factor is
PPARg. Out of the three known PPARg isoforms
expressed in adipocytes, only PPARg2 seems to be the
adipocyte-differentiation regulating splice variant
[113]. Although first discovered as an orphan recep-
tor, it is now certain that 15-deoxy-delta (12,14)-
prostaglandin J2 functions as the endogenous ligand
of PPARg [114, 115]. Externally added thiazolidine-
dione (TZD) compounds may also activate this
receptor providing novel tools to steer differentiation
in vitro.
Aside from studies on adipocyte precursor cells, ESCs
provide another powerful model to further under-
stand the early stages of adipogenesis. Ten years ago,
the first report of ESCs being capable of adipogenic
differentiation was published by Dani and coworkers
for murine cells [88]. In their paper, they described
that adipocytic colonies arose when ESCs were
exposed to all-trans retinoic acid (RA) during days
2–5 of differentiation followed by stimulation with
the adipogenic hormones insulin and triiodothyronine
(T3). In contrast, ESCs were not responsive to RA
after day 5 and treatment with neither rosiglitazone, a
PPAR agonist of the TZD family, nor fatty acid 2-
bromopalmitate induced adipogenesis at this stage of
differentiation. Captivatingly, the restrictiveness of
the permissive period for RA induction to differ-
entiation days 2 to 5 coincides with the expression of
Brachyury, the gene expressed during primitive streak
formation in vivo. Underlying the hypothesis that
adipocytes form out of the mesoderm, this strongly
suggests that RA would act during a time of in vitro
differentiation which corresponds to primitive streak
formation in vivo.
However, based on our own data, which suggests that
Brachyury expression is accompanied by increased
activity of the CatnB/TCFaxis in the nucleus [N. I. zur
Nieden, unpublished data], and the fact that RA
treatment, however,will inhibit this activation [116], it
is questionable that RA treatment during early ESC
differentiation truly increases the output of mesoder-
mal cells. Indeed,Kawaguchi et al. [117] have reported
that treatment with RA on differentiation days 2 to 5
markedly decreased Brachyury expression in mESCs.
Moreover, a recent study by Billon et al. [118] rather
suggests that adipocytes in ESC cultures are of neural
crest origin, which seems to be a likely hypothesis as
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RA treatment may also enhance the yield of neural
cells in ESCs.
Furthermore, our group has previously shown that
BMP-2 also can induce the adipogenic program in
murine ESCs depending on specific co-factors. To-
gether with insulin, BMP-2 can activate adipocyte-
specific expression patterns, including transcription of
PPARg andC/EBPa (Fig. 5), but also genes expressed
in more mature functional adipocytes, such as GLUT-
4 [104].
Adipocytes can also be derived fromhumanESCs and
MSCs with rosiglitazone [119, 120]. Specifically, in
ESCs spontaneous embryoid body formation was
induced with no specific adipogenic factors and
subsequently, rosiglitazone was added on day six of
differentiation. The altered timing of induction factor
usage is simply due to the fact that progression of
differentiation is generally slower in human ESCs as
compared to mouse ESCs. With longer population
doubling times in human ESCs, Brachyury is ex-
pressed on day 7 and not on day 3 as in murine cells
(Fig. 4). Two days into the addition of rosiglitazone,
serum concentrations were increased from 10% to
20%. The human ESC-derived adipocytes that sub-
sequently formed were shown to express PPARg2 at
very low levels and the three adipocyte markers
ADD1, adiponectin and aP2 only after 20 days in
differentiation medium. Again, timing of differentia-
tion is not congruent with murine ESC adipogenesis,
as murine ESCs express most adipogenic markers
after two weeks of in vitro differentiation (Fig. 5).
However, the succession of certain differentiation
steps seems to be similar in both species. The fact that
progenitor differentiation was induced spontaneous-
ly by some serum component in human ESCs
supports the notion that rosiglitazone treatment
acted on the progenitors that had formed during the
inductive phase, a process that is also seen in murine
ESC adipogenesis. It remains unclear whether these
progenitors are mesodermal or rather neural crest
progenitors. Based on the presented data however, it
can be hypothesized that both murine ESCs as well as
human ESCs closely follow the stepwise adipogenic
differentiation program described for pre-adipose cell
lines above: a permissive period for a) the commit-
ment of progenitors to adipocyte-progenitors and b)
for terminal differentiation requiring adipogenic hor-
mones.
Chondrogenesis
As we have summarized for adipogenesis, activation
of certain signaling pathways and their downstream
targets such as lineage-specific transcription factors
seem to exclusively regulate the progression into
mesodermal lineages.Differentiation of ESCs into the
chondrogenic lineage cannot only be enhanced by
transcriptional activation of target genes by external
soluble factors, but also by co-culture with limb bud
progenitor cells [121]. Co-culture systems have the
advantage of allowing direct cell-cell-contact poten-
tially leading then to the activation of signaling
pathways that are dependent on the intercellular
coupling of two cell types. Moreover, secreted auto-
crine and paracrine molecules can effect the respec-
tive other cell more readily. A major shortcoming of
this technique, however, is the difficulty of separating
the cells from one another for subsequent trans-
plantations or adequate in vitro analyses.
In addition to their role in adipogenesis reviewed
above, BMPs as soluble factors can also initiate the
chondrogenic program. Short term BMP-2 expression
is sufficient to induce the chondrogenic program in
MSCs [122]. During chondrogenic differentiation, the
MSCs also constantly express TGFb1, b2, b3 and b4
Figure 5. Expression profiling of
ESC-derived adipocytes. The ex-
pression level of adipocyte-spe-
cific transcription factors and
markers of the mature adipocyte
phenotype were determined by
quantitative PCR. Expression of
genes of interest was normalized
to GAPDH, a housekeeper in
ESC differentiation. Expression
in adipocyte cultures is repre-
sented as fold-induction in re-
spect to spontaneously differen-
tiating non-induced controls.
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[123]. Furthermore, it has been suggested through
purification of a flk+PDGFRa- progenitor population
differentiated fromESCs and the subsequent addition
of TGFb3 that chondrogenesis in ESCs follows both a
TGFb-dependent and a TGFb-independent pathway
[124]. The addition of BMP-4 at later stages of the
culture resulted in the formation of hyaline cartilage,
but early supplementation was rather detrimental.
The described study thus implies that chondrogenesis
in ESCs follows two critical steps first requiring TGFb
then followed by BMP-4. However, this is after
mesoderm has been committed and the flk+PDGFRa-
mesodermal progenitors were isolated for further
culture. Kramer et al. [89] on the other hand have seen
a positive effect of BMP-4 as well as BMP-2 on
chondrogenesis in ESCs by adding these factors in the
early phase immediately after a mesendodermal state
has been reached. Our group has shown previously
that continuous BMP-2 supplementation during all
phases resulted in an over 37-fold increase in collagen
type IIb expression compared to early supplementa-
tion alone [104].
The described studies give credence to the fact that
induction of chondrogenesis byBMP-2 commences on
day 3 of differentiation, illustrating that BMP-2 can
act to enhance the hemangioblast population. How-
ever, the enforced supplementation of BMP-2 until
chondrocytes are mature (differentiation day 32)
seems to support the notion that BMP-2 also regulates
the lineage specification programs at later time points
as described in Nakayama et al. [124].We will not rule
out thatBMP supplementation could be halted inmid-
phase chondrogenesis and re-initiated in the late
phase of development to further augment chondro-
genesis. Similar to the division of adipogenesis into
specific stages, it seems thus appropriate to stage
chondrogenic differentiation into four phases: I)
differentiation initiation, II) mesoderm formation
(BMP-dependent), III) a TGFb responsive period
and IV) a second BMP conductive phase.
Osteogenesis
Mineralization of ESCs and MSCs has been shown to
be triggered by b-glycerophosphate and ascorbic acid
[90–92, 125]. In vitro differentiation into osteoblasts
from both stem cell sources closely resembles in vivo
bone formation, also travelling through different
phases just like adipogenesis and chondrogenesis. In
ESC osteogenesis, at least four phases can be distin-
guished: I) a proliferation stage is followed by II)
mesenchymal commitment, III)matrix deposition and
finally IV)matrix mineralization. Each of these stages
is characterized by the expression of lineage-specific
genes. In ESCs, according to current protocols, phase I
and II occur spontaneously upon removal of LIF and
differentiation initiation in hanging drops [92]. Osteo-
genesis is then induced in phase III with the addition
ofVD3 [92] or dexamethasone [91, 126]. The following
five days of phase III of osteoblast induction show a
small increase in Runx2 accompanied by osteopontin
and collagen type I expression [92]. However, the
bone-specific isoform of alkaline phosphatase (ALP)
known to up-regulate in early osteogenesis was found
to peak in RNA expression and enzyme activity on
differentiation day 15 [92]. This enzyme precedes the
osteoblast phenotype and is thought to play a role in
the initiation of mineralization. The expression of
ALP was followed by osteopontin expression in
murine ESC osteogenesis. The final week of osteo-
genesis in vitro is marked by an increase in Runx2
followed by a second peak of ALP expression, and
finally osteocalcin and bone sialoprotein expression,
which mark the mature osteoblast phenotype [92].
Furthermore, overexpression of osterix, the second
major osteoblast-specific transcription factor along-
side Runx2, is sufficient to initiate osteogenesis in
ESCs upregulating osteocalcin expression and trans-
locating Runx2 into the nucleus, where it can activate
transcription of osteoblast-specific target genes [127].
Osterix itself seems to regulate its own transcription
through a positive feedback-loop as osterix over-
expressing ESCs show enhanced osterix expression on
day 7 of differentiation. Here, dexamethasone syn-
ergistically enhances osterix-induced osteogenesis
when added in late osteogenic phase III. In our
hands, osterix is endogenously expressed on day 6 of
differentiation in the osteogenic induction phase,
when mesodermal progenitors are in the transition
phase towards committing an osteogenic precursor
(data not shown). Thus, it appears that dexametha-
sone acts down-stream of osterix further committing
the cells to an osteoblast fate. Ultimately, through the
expression of certain genes the stage of osteoblast
differentiation in vitro can be determined.
Whereas adipogenesis and chondrogenesis occur
simultaneously in the same culture dish in ESCs,
chondrogenesis and osteogenesis seem to be mutually
exclusive. BMP-2 alone can not support mineraliza-
tion of ESCs, but induces expression of osteocalcin
and osteopontin [104]. Addition of BMP-2 together
with VD3 augments the osteogenic response of the
cells, but is unable to meet the levels that are attained
by VD3 alone. However, chondrogenic cultures can
convert to mineralized osteoblasts when VD3 is given
on differentiation day 20, arguing in favor of an
involvement of BMP-2 in endochondral bone forma-
tion. Likewise, BMP-2 has a supportive effect on
osteoblast cultures in differentiation phase IV [116].
Aside from inducing osteogenesis, VD3 has been
indicated to enhance osteoclast lineage development
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in ESCs [128]. Hence, both cell types characteristic for
functional bone, the osteoblast and the osteoclast, can
be found in VD3 induced ESCs (Fig. 3), rendering the
VD3 model an important in vitro system that allows
the study of cellular interactions that normally occur
in bone tissue in vivo.
How Wnt signaling controls cell fate
Based on the expression pattern of the presented
lineage markers adipo-, chondro- and osteogenesis
can be staged according to the differentiation pro-
gression. Captivatingly, all three differentiation paths
seem to be regulated in stages. In the following
paragraphs, we will present evidence for the fact that
each progression into the next differentiation stage is
accompanied by a switch from non-canonical Wnt
signaling to canonical Wnt signaling or vice versa.
The question arises how Wnts can exert diverse
functions in stem cells. The activation of downstream
targets is likely to be mediated by cell-type specific
intrinsic properties and expressed co-activators aswell
as mechanical properties of the cellular environment;
which is not only true for stem cell maintenance, but
also differentiation. Whereas in undifferentiated
ESCs, CatnB binds to LEF/TCF transcription factors
leading to transcription of cell cycle regulatory genes,
CatnB can also undergo direct binding to other co-
activators such as Early B-cell Factor 2 (EBF2)
regulating RANK-RANKL during osteoblast-de-
pendent osteoclastogenesis [129]. Furthermore, bind-
ing of the CatnB/LEF-TCF-complex to Smads has
been described in response to TGFb andBMPs during
development of the Speemans organizer in Xenopus
[130, 131]. With regard to osteoblast differentiation, a
functional binding site for LEF1was found adjacent to
the proximal Runx2-binding site in the osteocalcin
promoter. In transcription assays, LEF1 repressed
Runx2-induced activation of the mouse osteocalcin 2
promoter in several osteoblast lineage cell lines [132].
The interaction between theDNA-binding domains of
Runx2 and LEF1, as a nuclear effector of the Wnt/
CatnB signaling pathway, was found crucial for LEF1-
mediated repression of Runx2 and essential for
osteoblast proliferation and normal skeletal develop-
ment. The internuclear presence of these co-factors in
turn depends on the extracellular environment of the
cell and induction of other signaling pathways (i.e.
TGFb, BMPs) activated by extracellular stimuli. In
conclusion, the output of Wnt signaling is highly
determined by a combined activity of multiple factors.
Adipogenesis
Wnts that induce a signaling pathway through PPAR,
specifically the non-canonical Wnt5a, regulate the
growth, differentiation, apoptosis and insulin sensi-
tivity of the differentiating adipocytes [133]. How-
ever, during early adipogenesis, a timely activation-
inactivation of the Wnt pathway is essential for the
induction of PPARd and PPARg [134, 135]. Canonical
Wnt signaling is responsible for keeping pre-adipo-
cytes in the undifferentiated state, promoting cell
proliferation with the activation of cyclin D1 and c-
myc while inhibiting PPAR. Cyclin D1 and c-myc
inhibit by binding directly to PPAR and the C/EBPa
transcription factor, respectively [136, 137]. More-
over, the expression of C/EBPa coincides with the
phosphorylation of CatnB and subsequent degrada-
tion. Consequently, in order to facilitate differentia-
tion, nuclear CatnB activity is down-regulated and
non-canonical signaling is switched on [138]. This
process is dependent on GSK-3b, which phosphor-
ylates CatnB, targeting it for degradation in the
proteasome.
Simultaneous induction of PPARg expression sug-
gests that CatnB could block PPARg expression and
PPARg in turn can direct CatnB for proteasomal
degradation. Activation of canonical signaling
through Wnt1, Wnt10b and a CatnB mutant that
increases CatnB stability has been shown to inhibit
3T3-L1 adipocyte differentiation, a cell line common-
ly used as a model for white adipocyte differentiation,
suggesting that Wnt10b mRNA, free CatnB and
adipogenesis are inversely correlated [85, 139]. In
particular, Wnt10a has been shown to exert an
inhibitory function in the differentiation of white
adipose tissue through down-regulation of the tran-
scription factors C/EBPa and PPARg. The distinction
between Wnt10a and 10b in white versus brown
adipocytes suggests involvement of diverse Wnt
family members in the regulation of the two types of
adipose tissue. Wnt10b is expressed in preadipocytes,
decreasing in differentiating adipocytes thereby in-
hibiting adipogenesis and promoting osteogenesis
[140]. Furthermore, Wnt10b shifts cell fate towards
the osteoblast phenotype by regulating the expression
of Runx2, Dlx5 and osterix and down-regulating the
expression of C/EBPa and PPARg. Similarly, Wnt3a
overexpression inhibits PPARg2 expression and adi-
pocyte fatty acid binding protein in C3H10T1/2 cells
[141].
Another link betweenWnt signaling and adipogenesis
can be found in GSK-3b, which in addition to
phosphorylation of CatnB can also phosphorylate C/
EBPa. Here, insulin treatment dephosphorylates
Thr222 and Thr226 residues of C/EBPa through
inactivation of GSK-3b and leads to a decrease in C/
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EBPamRNAand protein [142]. Treatment of 3T3-L1
adipocytes with the GSK-3b inhibitor, lithium chlo-
ride, thus blocks differentiation [143].
Further confirmation of involvement of non-canon-
ical Wnt signaling in adipogenesis stems from the
studies of Bandyopadhyay et al. [138] in ESCs, who
have shown that insulin can activate PKCl, a non-
canonicalWnt downstream target, and thus stimulates
glucose transport in undifferentiated ESCs. Both
phenomena, the activation of PKCl as well as the
glucose transport, are dependent on activation of
proline-rich tyrosine protein kinase 2 (PYK2), the
ERK pathway and phospholipase D (PLD), but are
independent of PI3K [144]. In contrast, during differ-
entiation of theESCs to lipid filled adipocytes induced
by insulin, dexamethasone and isobutylmethylxan-
thine, this dependency was completely reversed.
Insulin effects on PKCl and glucose transport were
in that case dependent on PI3K, rather than PYK2/
ERK/PLD. These findings suggest that atypical PKCs
are required for insulin-stimulated glucose transport
regardless of the downstream signaling cascade.
The listed evidence suggests that progression of the
adipogenic program might be controlled by fluctua-
tions in nuclear CatnB activity achieved by switching
from canonical to non-canonical Wnt signals. More-
over, increased expression of canonical Wnt pathway
genes inversely correlates with the size of adipogenic
cells suggesting a compensatory increase of energy
partitioning or lipid accumulation to the existing
adipocytes resulting from impairment in the gener-
ation of new adipocytes [145].
Chondrogenesis
The role of the Wnt pathway in chondrocyte differ-
entiation also revolves around the location and
expression of CatnB. Although the canonical pathway
is involved in mesenchymal condensations, other
proteins such as the chondrocyte specific transcription
factor Sox9 are also involved. In fact, CatnB and Sox9
negatively regulate each other and it has been
suggested that CatnB binds Sox9 at its transactivation
domain thus effectively inhibiting its activity [146].
Similar to the switch between canonical and non-
canonical signaling described for adipogenic differ-
entiation events, CatnB expression levels are high in
prechondrogenic mesenchyme decreasing while cells
travel through differentiation to become mature
chondrocytes [147] thus allowing for Sox9 expression
to increase. Constitutively active CatnB inhibits
chondrocyte differentiation by reducing collagen
type II and Sox9 expression in cultured chicken
chondrocytes [147] and proliferation in the growth
plate in vivo [148]. Similarly, Wnt5a may promote
chondrocyte differentiation in the distal limb bud by
inhibiting canonical activity [149]. As such, Wnt5a-/-
embryos are characterized by inhibition of chondro-
genesis in the distal limb as a result of elevated
CatnB.
Progressing through to hypertrophy canonical Wnt
signaling via CatnB has then to be up-regulated again.
For example, in the developing chick limb, constitu-
tively active CatnB promotes chondrocyte hypertro-
phy [150] whereas forced expression of Wnt5a will
delay chondrocyte maturation to hypertrophic stages
[75].
In spite of existing evidence with regard to stage
specific regulation of chondrogenesis by canonical or
non-canonical signaling, it is believed that the non-
canonical pathway is essential for chondrogenesis as
the canonical pathway is essential for osteogenesis
[151]. Besides, the inactivation of CatnB will cause
chondrocyte formation in an osteoinducing medium,
thus reinforcing the idea that CatnB regulation is key
to determining the fate of an osteo-chondro precursor
[148]. Further evidence shows that the up-regulation
of CatnB precedes osteoblast differentiation during
intramembraneous ossification, whereas CatnB is
down-regulated in the chondrogenic condensations
and up-regulated in the surrounding cells during
endochondral bone formation.
In conclusion, the canonical pathway inhibits pro-
gression of chondrocyte differentiation, enhances
endochondral bone formation and promotes chon-
drocytematuration similar to what is seen during ESC
differentiation, where canonical signaling is required
during early differentiation and late-stage chondro-
genesis.
Osteogenesis
As we have presented, it seems likely that discrep-
ancies in CatnB actions during chondrogenic differ-
entiation simply reflect the stage-and dose-dependent
requirement for canonical signaling. In osteogenesis,
many Wnt pathway molecules show contradictory
phenotypes depending on dose, time of treatment, cell
line, and model organism.
The function of CatnB during in vivo bone develop-
ment was shown byHill et al. [152] with the deletion of
CatnB in the mesenchyme using a Prx-Cre system.
Here, CatnBwas deleted in the forelimb and hindlimb
mesenchyme starting with E10.5. The resulting phe-
notype of the CatnBDPRX/- mutation resulted in arrest
of early osteoblast differentiation and repression of
mineralization leading to a truncation in the limbs.
The cause of this phenotype was the down-regulated
expression of osterix and complete loss of osteocalcin
expression. Interestingly, a gain-of-function mutant
generated by the same group showed a similar
phenotype.
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Although these in vivo studies suggest that CatnB
plays a role in osteogenesis, this role may vary in vitro
depending on the cell line, stage of differentiation, and
amount of CatnB protein present. Canonical Wnt
signaling is thought to support osteogenic differentia-
tion from both precursor lines and stem cell lines in
vitro [153]. However, the exact effect of the canonical
pathway on osteoblast formation is very stage-specif-
ic. Logan and Nsse [64] suggested that CatnB blocks
the differentiation of mesenchymal cells into skeletal
precursors. By artificially increasing CatnB levels
within the cell using lithium chloride treatment, ALP
expression in the multipotent cell line C3H10T1/2 can
be induced, but not sufficiently to induce osteocalcin
expression. However, CatnB does increase osteocal-
cin promoter activity in MC3T3 cells, which is a more
committed osteoblast cell line [132].
Canonical signaling seems to positively and negatively
regulate the action of Runx2 on certain osteoblast
specific promoters. In a gain-of-function study, CatnB
enhanced LEF1-mediated repression of Runx2. Fur-
thermore, LEF1 as well as TCF1 and TCF4 repressed
Runx2 activity on the osteocalcin promoter [132, 154].
LEF1 has been shown to delay osteoblast differ-
entiation in MC3T3 pre-osteoblast cells and regulate
the expression of extracellular matrix proteins [155].
However, in different cellular contexts, Runx2 and
LEF1/TCF cooperate to activate gene expression
[156, 157].
It has been suggested that the stage of differentiation
may be important in understanding the effect of the
canonical pathway on osteogenesis. In ESCs, nuclear
CatnB activity needs to be blocked in order for the
cells to transgress from a mesodermal progenitor to a
more committed osteoprogenitor (Fig. 2) [90]. The
concept that canonical signaling is then suppressed in
mature osteoblasts at later stages of differentiation
[158] is supported by the increase in Dickkopf 1 and
other Wnt antagonists in mature osteoblasts [159].
Moreover, CatnB is expressed in osteoblasts and not
in osteocytes [160]. We can only speculate that the
difference in CatnB effects might be attributed to the
differentiation stages that these different model
systems represent. Rodda and McMahon [161] also
suggested that commitment within the osteoblast
lineage requires sequential, stage-specific canonical
signaling to promote osteogenesis and block chon-
drogenic programs of cell fate specification. Here, the
conditional deletion of CatnB in early osteoblast
progenitors and Runx2+Osx+ precursors resulted in
the osteoblasts failing to mature, characterized by
decreased osteocalcin expression. Instead these im-
mature osteoblast progenitors were converted into
chondrocytes. In conclusion, progression of differ-
entiation through to mature osteoblasts is dependent
on fluctuations in nuclear CatnB activity achieved
through a switch between canonical and non-canon-
ical Wnt signaling.
Conclusion
Lineage specification of mesenchymal progenitors,
either adult stem cells or ESC-derived, seems to be
CatnB dependent and independent as CatnB seems to
regulate only a subset of all genes required for proper
and terminal differentiation. The described effects in
the three lineages under discussion in this review may
appear controversial at first sight, but clearly indicate
that Wnt signaling must be tightly controlled in vivo
and in vitro in all lineages to regulate proliferation and
differentiation and thus the development of tissues.
Specifically, it seems to be a switch between canonical
and non-canonical Wnt signaling that depending on
the time of differentiation it occurs at directs the cell
into different fates.However, if these switches occur in
the specification of all lineages, then what is it that
specifies a chondrocyte rather than an osteoblast?
Here, it will be critical to identify the regulators that
turn the switch on or off at specific times of the
differentiation path.
With increasing knowledge of pathways involved in
fate decisions it becomes clear that directing differ-
entiation with growth factors in vitro has to closely
resemble the program that is initiated in vivo. Cell
culture media and the timing of their application are
becoming increasingly complex. In return, delineating
the pathways that govern stem cell differentiation in
vitro could ultimately help us understand how adipo-
genic tissue, bone and cartilage are generated in vivo.
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